key: cord-0709294-825hjq1z
authors: Escribano, Pilar; Sánchez-Pulido, Ana-Erika; González-Leiva, José; Valero-López, Iván; Catalán, Pilar; Muñoz, Patricia; Guinea, Jesús
title: Different performance of three point-of-care SARS-CoV-2 antigen detection devices in symptomatic patients and close asymptomatic contacts: a real-life study
date: 2022-02-21
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2022.02.014
sha: 73d5ee3cc3e4b6fd90712d022bc977bb8857122e
doc_id: 709294
cord_uid: 825hjq1z

OBJECTIVES: PCR on nasopharyngeal exudates, the cornerstone of the detection of SARS-CoV-2, is time-consuming and commonly unavailable at primary health care centres. Detection of viral nucleocapsid antigens using lateral flow point-of-care tests is helpful for the early triage of patients who attend health care facilities. METHODS: Prospective study carried out in clinically suspected cases and close asymptomatic contacts who attended a primary care centre (Madrid, Spain) for SARS-CoV-2 detection. Patients were divided into three 300-patient cohorts (n=200 symptomatic cases and n=100 close asymptomatic contacts per cohort). Three antigen detection tests (SGTI-Flex COVID-19 Ag, Panbio(TM) COVID-19 Ag Rapid Test Device, and GSD NovaGen SARS-CoV-2 Ag Rapid Test) were used and compared. Paired nasopharyngeal exudates were obtained, one swab for PCR and the other for antigen detection. Each antigen detection test was evaluated on one cohort. RESULTS: All tests showed invariably 100% specificity. Sensitivity in clinically suspected patients was 68.9% (95 %CI: 55.7 - 80) (SGTI-Flex), 71.1% (95 %CI: 55.6 - 83.6) (Panbio(TM)), and 84.6% (95 %CI: 72 - 93.1) (NovaGen) and 84.6% (95 %CI: 54.5 - 98.1), 33.3% (95 %CI: 11.8 - 61.6), and 55.6% (95 %CI: 30.7 - 78.4) in close asymptomatic contacts, respectively. Sensitivity was systematically higher in samples yielding positive PCR results with Ct ≤20. CONCLUSIONS: We found considerable test-to-test antigen detection variations among patients with clinical suspicion of COVID-19 and close asymptomatic contacts. Negative antigen results, regardless the test used, should be confirmed by PCR.

Objectives: PCR on nasopharyngeal exudates, the cornerstone of the detection of SARS-24

CoV-2, is time-consuming and commonly unavailable at primary health care centres. 25

Detection of viral nucleocapsid antigens using lateral flow point-of-care tests is helpful for the 26 early triage of patients who attend health care facilities. 27

Methods: Prospective study carried out in clinically suspected cases and close 28 asymptomatic contacts who attended a primary care centre (Madrid, Spain) for SARS-CoV-2 29 detection. Patients were divided into three 300-patient cohorts (n=200 symptomatic cases 30 and n=100 close asymptomatic contacts per cohort). Three antigen detection tests (SGTI-Flex 31 COVID-19 Ag, Panbio TM COVID-19 Ag Rapid Test Device, and GSD NovaGen SARS-CoV-2 Ag 32

Rapid Test) were used and compared. Paired nasopharyngeal exudates were obtained, one 33 swab for PCR and the other for antigen detection. Each antigen detection test was evaluated 34 on one cohort. 35

Results: All tests showed invariably 100% specificity. Sensitivity in clinically suspected 36 patients was 68.9% (95 %CI: 55.7 -80) (SGTI-Flex), 71.1% (95 %CI: 55.6 -83.6) (Panbio TM ), and 37 84.6% (95 %CI: 72 -93.1) (NovaGen) and 84.6% (95 %CI: 54.5 -98.1), 33.3% (95 %CI: 11.8 -38 61.6), and 55.6% (95 %CI: 30.7 -78.4) in close asymptomatic contacts, respectively. Sensitivity 39 was systematically higher in samples yielding positive PCR results with Ct ≤20. 40

The clinical presentation of coronavirus disease (COVID-19) ranges from asymptomatic 45 or nonspecific mild illness, to severe pneumonia with acute respiratory distress syndrome, 46 progression to severe and fatal respiratory failure, and death (1) . COVID-19 spreads easily and 47 quick laboratory testing is key in helping halt the disease by recommending infected patients 48 to self-isolate. 49

Detection of SARS-CoV-2 viral RNA in nasopharyngeal exudate samples is the 50 cornerstone of COVID-19 diagnosis (2). However, PCR is a time-consuming procedure 51 commonly unavailable at primary health care centres that alters the routine in the laboratory 52 by increasing the workload (3). Detection of viral nucleocapsid antigens using immunoassays 53 based on lateral flow point-of-care tests are helpful for the early triage of patients who attend 54 health care facilities. The WHO supports antigen testing for the detection of SARS-CoV-2 in 55 areas where PCR is not available, when it implies long turnaround times in reporting results, in 56 the context of outbreak investigations or areas where prevalence is high, or for screening of 57 asymptomatic positive contacts (4). 58

Few studies have evaluated and compared antigen detection in symptomatic patients 59 and close asymptomatic contacts who attend hospital facilities, and mostly have been 60 conducted using the Panbio TM test (5-9); furthermore, studies that have evaluated different 61 tests in these two groups are insufficient (10, 11). 62

It is thus unknown if the performance of antigen detection differs in patients with mild 63 disease who attend primary care centres. Here, we report a real-life study in which we 64 assessed the performance of three antigen detection tests in both patients with clinical 65 J o u r n a l P r e -p r o o f suspicion of mild forms of COVID-19 and close asymptomatic contacts who attended a 66 primary health care centre for SARS-CoV-2 detection. 67

Study patients and definitions. Prospective study carried out with patients who 69 attended the Pavones primary care centre (Madrid, Spain) between February 3 and April 14, specificity, positive predictive value, and negative predictive value (95% confidence interval, 121 95%CI) were calculated separately for each of the three antigen detection tests using PCR as 122 the gold standard. Viral load analysed is based on median Ct values and differences were 123 compared using the non-parametric Mann-Whitney U test; sensitivity was reassessed based 124 on Ct results (Ct<20 or Ct≥20). Scatter plots were used to represent Ct values (Graph Pad 125 7 19 included in the study, 63% were female with median age of 44 (IQR, 30-58) years. Fever (> 134 38 ºC), headache, sore throat, arthromyalgia, and cough were the most frequent symptoms 135 (Table 1) . Patients with positive test results (PCR, antigen detection, or both) had fever 136 significantly more frequently, more cough, anosmia, ageusia, and arthromyalgia than patients 137 with negative determinations (P<0.05); in contrast, they had less dyspnoea, sore throat, and 138 thoracic pain (P<0.05) ( Table 1 ). Variables in patients in the three groups of tests were 139 comparable, with the exception of cough, dyspnoea, headache, and number of days from 140 symptom onset to sampling, which showed inter-group variations (Table 2 ). Median number 141 of days for the collection of nasopharyngeal exudates after the onset of symptoms was two 142 (IQR, 1-4), with statistically significant differences among tests: SGTI-Flex test (2, IQR 1-4) 143 compared with the Panbio TM (3, IQR 1-4) and the NovaGen tests (2, IQR 1-3) (P < 0.05) ( Table  144 2). Samples for antigen detection were collected within the recommended period from the 145 onset of symptoms or close contact. (Table 3) . 152

contacts. From the 300 close asymptomatic contacts, 53.7% female with median age of 47 tests were seen: SGTI-Flex test (4.5, IQR 2.25-6) compared with the Panbio TM (5, IQR 4-7) and 157 the NovaGen tests (5, IQR 3-7) (P < 0.05). 158 SARS-CoV-2 positive detection prevalence (asymptomatic carriers) was 15.3%, ranging 159 from 13% (SGTI-Flex test) to 18% (NovaGen test) (P > 0.05) between cohorts. Sensitivity of 160 SGTI-Flex, Panbio TM , and NovaGen was 84.6% (95 %CI: 54.5 -98.1), 33.3% (95 %CI: 11.8 -161 61.6), and 55.6% (95 %CI: 30.7 -78.4), respectively. All tests showed invariably 100% 162 specificity and positive predictive values. Sensitivity was systematically higher in samples 163 yielding positive PCR results with Ct ≤20 (Table 3) . (Figure 3) . 187

Our study shows that the three evaluated SARS-CoV-2 antigen detection tests do not perform in clinically suspected cases, whereas the SGTI-Flex test shows the highest sensitivity in close 219 asymptomatic contacts. Being aware of the differences in test-to-test performances is key 220 when screening for SARS-CoV-2, particularly in close asymptomatic contacts and symptomatic 221 patients, for whom antigen-negative determinations must be confirmed by PCR.

headache, and dyspnoea more frequently than patients in the other two cohorts. Better 225 performance of the three tests was seen when positive PCR samples were grouped by Ct 226 values (Ct ≤20), although these differences among samples within each cohort of patients do 227 not explain performance dissimilarities either. An alternative explanation to the discrepancies 228 between PCR and antigen detection may be a poor quality of the sample collected for antigen 229 detection, given that both swabs were not dipped into viral transport medium. However, had Our study is limited by the fact that we did not study the performance of the three tests 242 in the same pool of samples. However, we opted for such an approach to preserve the 243 sensitivity of antigen detection, as testing the three tests simultaneously would have required 244 dilution of samples upon discharge into broth viral transport medium. Furthermore, we do not 245 know if asymptomatic carriers could have developed any kind of symptoms in the forthcoming 246 days after the sample collection. 247

We conclude there are considerable test-to-test antigen detection variations among 248 patients with clinical suspicion of COVID-19 and close asymptomatic contacts. Such 249 differences should be taken into account when choosing the tests for SARS-CoV-2 screening in 250 patients attending primary care. Negative antigen results, even when the test with the highest 251 sensitivity for the detection of infected subjects is used, does not preclude PCR confirmation. 252

The authors are grateful to Dainora Jaloveckas for manuscript editing assistance. 

We would like to thank the following members of the COVID-19 study group Hospital 264

Gregorio Marañón [Adán (Iván), Adán (Javier), Alcalá (Luis), Alonso (Roberto), Álvarez-Uría 265 

COVID-19, 293 frailty and long-term care: Implications for policy and practice

Laboratory Diagnosis of COVID-19: Current 296 Issues and Challenges

Evaluation of seven 298 commercial RT-PCR kits for COVID-19 testing in pooled clinical specimens

Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid 301 immunoassays interim guidance

Multi-site assessment of 305 rapid, point-of-care antigen testing for the diagnosis of SARS-CoV-2 infection in a low-306 prevalence setting: A validation and implementation study

Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after 310 the onset of symptoms

Analytical and

Call for a pan-European COVID-19 response must be comprehensive

Nasopharyngeal Panbio COVID-19 Antigen Performed at Point-of-Care Has a High 318 Sensitivity in Symptomatic and Asymptomatic Patients With Higher Risk for Transmission

Implementing 321 SARS-CoV-2 Rapid Antigen Testing in the Emergency Ward of a Swiss University Hospital: The 322 INCREASE Study

Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-CoV-2

point-of-care 327 antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. The Cochrane 328 database of systematic reviews

Comparative evaluation of Panbio and SD Biosensor antigen rapid 331 diagnostic tests for COVID-19 diagnosis

Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus 334 disease (COVID-19) patient samples

Evaluation of a rapid antigen test 336 (Panbio COVID-19 Ag rapid test device) for SARS-CoV-2 detection in close asymptomatic 337 contacts of COVID-19 patients

Diagnostic 339 performance and characteristics of anterior nasal collection for the SARS-CoV-2 antigen test: a 340 prospective study

The evaluation of a 342 newly developed antigen test (QuickNavi-COVID19 Ag) for SARS-CoV-2: A prospective 343 observational study in Japan

Field 345 evaluation of a rapid antigen test (Panbio COVID-19 Ag Rapid Test Device) for COVID-19 346 diagnosis in primary healthcare centres

Panbio rapid antigen test 348 for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary health care

The SARS-CoV-2 Nucleocapsid Protein and Its Role in Viral 351

Biological Functions, and a Potential Target for Drug or Vaccine Mitigation